Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis

CSF α-Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease

(2017) Fransje E. Reesink et al.   JOURNAL OF ALZHEIMERS DISEASE

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

(2013) Penny F. Whiting   ANNALS OF INTERNAL MEDICINE

Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity

(2013) K. D. van Dijk et al.   EUROPEAN JOURNAL OF NEUROLOGY

Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy

(2013) Malin Wennström et al.   PLoS One

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

(2012) Sara Hall et al.   ARCHIVES OF NEUROLOGY

Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's Disease

(2012) Min Jeong Park et al.   Journal of Clinical Neurology

Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects

(2012) Brit Mollenhauer et al.   NEUROSCIENCE LETTERS

Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease

(2011) Fuyuki Tateno et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease

(2011) Michael R. Sierks et al.   Integrative Biology

Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics

(2011) Manfred Gerlach et al.   JOURNAL OF NEURAL TRANSMISSION

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

(2011) Brit Mollenhauer et al.   LANCET NEUROLOGY

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

(2011) Lucilla Parnetti et al.   MOVEMENT DISORDERS

Detection of elevated levels of  -synuclein oligomers in CSF from patients with Parkinson disease

(2011) K. A. Bruggink et al.   NEUROLOGY

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

(2010) Min Shi et al.   ANNALS OF NEUROLOGY

Olfaction as a biomarker in Parkinson’s disease

(2010) James F Morley et al.   Biomarkers in Medicine

Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies

(2010) Brit Mollenhauer et al.   Biomarkers in Medicine

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

(2010) Zhen Hong et al.   BRAIN

Detection of elevated levels of  -synuclein oligomers in CSF from patients with Parkinson disease

(2010) T. Tokuda et al.   NEUROLOGY

Biological fluid biomarkers in neurodegenerative parkinsonism

(2009) Michael Eller et al.   Nature Reviews Neurology

Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

(2008) Brit Mollenhauer et al.   EXPERIMENTAL NEUROLOGY

Second consensus statement on the diagnosis of multiple system atrophy

(2008) S. Gilman et al.   NEUROLOGY

Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

(2008) Annika Öhrfelt et al.   NEUROSCIENCE LETTERS